HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today ...

Therefore, it's important for those suffering from rosacea, a chronic skin condition affecting an estimated 16 million Americans, to understand antibiotic resistance, what it means and ways to help ...

Dr Reddy’s Laboratories on Friday announced the launch of Doxycycline capsules 40 mg, in the US market. The drug is a therapeutic generic equivalent of ORACEA (doxycycline, USP) capsules (40 mg), ...

The global pharma major has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Doxycycline capsules, 40 mg.

Zydus Cadila has received approval from the US FDA to market its generic Doxycycline capsules used for the treatment of bacterial infections in the American market. The drug falls in the ...

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Capsules, 40 mg. At the time of ...

On Tuesday (April 9), the company, through a regulatory filing, informed investors that the US Food and Drug Administration (US FDA) had given the company approval to launch the first generic version ...

The drug will be available in one strength with a fixed dose to be taken once daily. (File) Global pharma major Lupin Limited on Tuesday announced that it has received tentative approval from the ...

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we ...